Galmed Pharmaceuticals Ltd.
GLMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $1 | $151 | $537 |
| - Cash | $5 | $3 | $2 | $3 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$2 | -$2 | $149 | $534 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$7 | -$7 | -$18 | -$33 |
| % Margin | – | – | – | – |
| Net Income | -$8 | -$7 | -$19 | -$32 |
| % Margin | – | – | – | – |
| EPS Diluted | -8.08 | -29.95 | -11.08 | -19.48 |
| % Growth | 73% | -170.3% | 43.1% | – |
| Operating Cash Flow | -$6 | -$6 | -$19 | -$33 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$6 | -$6 | -$19 | -$33 |